NEJM Journal Watch - General Medicine

Vaccination reduced all-cause mortality in cardiac patients and offered some protection against specific cardiovascular events.

Rates were decreasing steadily until the COVID-19 pandemic.

Elinzanetant appeared safe and effective through 52 weeks of follow-up in the trials that led to approval.

Supplementation with ω-3 fatty acids lowered CV-related morbidity and mortality during 2 years of follow-up.

This study provides more evidence that critically ill patients with acute kidney injury and pH ≤7.2 who received sodium bicarbonate are less likely to require renal replacement therapy.

In a randomized trial, femoral nerve block provided better short-term analgesia with fewer adverse effects.

In this landmark randomized trial, stenting was associated with fewer nondisabling strokes at 4 years.

Weekly semaglutide improved overall cardiovascular outcomes in such patients, whether ejection fraction was preserved or reduced.

In a retrospective study, GLP-1 agonists were associated with slower progression to cirrhosis.

A 14-day monitor detected more atrial fibrillation but did not affect hospitalization rates for stroke or hemorrhage.